CNS Pharmaceuticals Files 8-K: Security Holder Rights & Exhibits
Ticker: CNSP · Form: 8-K · Filed: Feb 21, 2025 · CIK: 1729427
| Field | Detail |
|---|---|
| Company | Cns Pharmaceuticals, Inc. (CNSP) |
| Form Type | 8-K |
| Filed Date | Feb 21, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing, corporate-actions
TL;DR
CNS Pharmaceuticals filed an 8-K on Feb 19, 2025, updating security holder rights and filing exhibits.
AI Summary
On February 19, 2025, CNS Pharmaceuticals, Inc. filed an 8-K report detailing material modifications to security holder rights and other events. The filing also includes financial statements and exhibits, with the company's principal executive offices located at 2100 West Loop South, Suite 900, Houston, Texas.
Why It Matters
This 8-K filing provides crucial updates on changes affecting CNS Pharmaceuticals' security holders and includes important financial and exhibit information for investors.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting material modifications and other events, not indicating immediate operational or financial distress.
Key Numbers
- 001-39126 — SEC File Number (Identifies the company's filing with the SEC.)
- 82-2318545 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- CNS Pharmaceuticals, Inc. (company) — Registrant
- February 19, 2025 (date) — Date of earliest event reported
- 2100 West Loop South, Suite 900, Houston, Texas 77027 (address) — Principal executive offices
- Nevada (jurisdiction) — State of incorporation
- 001-39126 (identifier) — SEC File Number
FAQ
What specific material modifications to the rights of security holders are detailed in this 8-K filing?
The filing indicates 'Material Modifications to Rights of Security Holders' as an item, but the specific details of these modifications are not provided in the provided text excerpt.
What are the 'Other Events' reported by CNS Pharmaceuticals, Inc. on February 19, 2025?
The filing lists 'Other Events' as a reported item, but the specific nature of these events is not detailed in the provided excerpt.
Where are the principal executive offices of CNS Pharmaceuticals, Inc. located?
The principal executive offices of CNS Pharmaceuticals, Inc. are located at 2100 West Loop South, Suite 900, Houston, Texas 77027.
What is the state of incorporation for CNS Pharmaceuticals, Inc.?
CNS Pharmaceuticals, Inc. is incorporated in Nevada.
What is the SEC File Number for CNS Pharmaceuticals, Inc.?
The SEC File Number for CNS Pharmaceuticals, Inc. is 001-39126.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 21, 2025 regarding CNS Pharmaceuticals, Inc. (CNSP).